Search results
Results from the WOW.Com Content Network
The stock of AcelRx Pharmaceuticals (NAS:ACRX, 30-year Financials) shows every sign of being possible value trap, according to GuruFocus Value calculation.
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -42.86% and -77.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...
Celebrations may be in order for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) shareholders, with the analysts delivering...
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035 , an experimental therapy for amyotrophic lateral sclerosis . AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, [ 1 ] and in the United States, as Relyvrio, in September 2022. [ 2 ]
We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results.
Cambrex Corporation is a Contract Development Manufacturing Organisation (CDMO) that provides drug substance, drug product and analytical services across the entire drug lifecycle, as well as active pharmaceutical ingredients (APIs). With over 2,200 employees in 7 countries across 13 locations, Cambrex operates in branded and generic markets ...
Akorn Operating Company LLC (Akorn Inc. prior to its bankruptcy) was an American generic pharmaceuticals manufacturer based in Lake Forest, Illinois. The company dealt in developing, manufacturing and marketing of generic and prescription drugs as well as animal and consumer health products. [1] It was a component of the NASDAQ Biotechnology Index.
AcelRx Pharmaceuticals Inc. has hired John Saia, most recently associate general counsel at drug distributor McKesson Corp., as its new top lawyer in the run-up to resubmitting its pain drug ...